Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

MMP/TNF inhibitors reported by Pfizer

Dec. 12, 1996

New antiinflammatory agents disclosed by DuPont Merck

Dec. 10, 1996

Another British Biotech compound reaches clinical stage

Dec. 9, 1996

FDA tentatively approves generic NSAID

Dec. 6, 1996

SKB, IDEC initiate phase III testing of antirheumatic antibody

Dec. 6, 1996

Connective Therapeutics acquires rheumatoid arthritis Rx from SKB

Dec. 6, 1996

Phase II trials begin on low-dose interferon alfa for Sjogren's syndrome

Dec. 5, 1996

COX-2 inhibitors under investigation at Glaxo Wellcome

Dec. 3, 1996

Reversible cysteine protease inhibitors reported by Arris

Nov. 28, 1996

Taiho antirheumatic agent possesses novel mechanism of action

Nov. 27, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...